Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2007-11-27
2007-11-27
Saoud, Christine J. (Department: 1647)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S192100, C514S002600, C514S012200, C530S350000, C536S023400
Reexamination Certificate
active
10830902
ABSTRACT:
Methods of preventing, reducing, or treating corneal transplant rejection to improve transplant survival in a subject in need thereof comprising administering an agent capable of blocking or inhibiting vascular endothelial growth factor (VEGF) are provided. The methods are useful for inhibiting or preventing corneal transplant rejection in a human subject who is the recipient of a transplanted cornea.
REFERENCES:
patent: 2005/0197291 (2005-09-01), Wiegand et al.
patent: 2006/0172944 (2006-08-01), Wiegand et al.
patent: WO99/13909 (1999-03-01), None
patent: WO00/75319 (2000-12-01), None
patent: WO03/072029 (2003-09-01), None
Phillips, A.J. (2001). The challenge of gene therapy and DNA delivery. J. Pharm. Pharmacol. 53:1169-1174.
Stagner et al. (2004). Beta-cell sparing in transplanted islets by vascular endothelial growth factor. Transplant. Proc. 36:1178-1180.
Yi et al. (2007). VEGF gene therapy for the survival of transplanted fat tissue in nude mice. J. Plast. Reconstr. Aesthet. Surg. 60:272-278.
Palùet al. (1999). In pursuit of new developments for gene therapy. J. Biotechnol. 68:1-13.
de Freitas et al. (2006). Causes and risk factors for graft failure in surgeries performed by physicians in fellowship training. Cornea. 25(3):251-256.
Yatoh, et al., TRANSPLANTATION, Vol. 66, No. 11, pp. 1519-1524, (1998).
Lai et al. Inhibition of Corneal Neovascularization by Recombinant Adenovirus Mediated Antisene VEGF RNA. (2002) Experimental Eye Research 75:625-634.
Cao Jingtai
Cursiefen Claus
Wiegand Stanley
Gregg, Esq. Valeta
Lockard Jon M
Regeneron Pharmaceuticals Inc.
Saoud Christine J.
LandOfFree
Method of treating corneal transplant rejection does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating corneal transplant rejection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating corneal transplant rejection will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3856184